Skip to main content
U.S Department of Health and Human Services (HHS) National Institutes of Health
HomeRG1662 in Individuals with Down Syndrome
Find more clinical trials

RG1662 in Individuals with Down Syndrome

Start: November 2011
End: September 2013
Enrollment: 33

What Is This Study About?

The purpose of this study is to assess the safety and tolerability of the experimental drug RG1662 in individuals with Down syndrome.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 30 Years

Must have:

++Males and nonpregnant, nonlactating females with a diagnosis of Down syndrome (confirmed by karyotype)++Parent or legal guardian/representative and caregiver willing to give written informed consent++Subject willing and consenting to participate

Must NOT have:

++Major depressive disorder not adequately controlled by a selective serotonin reuptake inhibitor or serotonin norepinephrine reuptake inhibitor++Clinical diagnosis of autistic spectrum disorder or attention deficit or hyperactivity disorder that makes study participation unlikely++Other primary psychiatric diagnosis++Evidence or clinical diagnosis of dementia++Personal history of cardiac abnormalities; patients that have previously undergone congenital heart surgery can be enrolled provided they have no residual complication requiring intervention (e.g., pacemaker)++Clinically significant obstructive pulmonary disease or asthma that is not adequately treated (oral steroids are not allowed)++Thyroid dysfunction that is not adequately controlled and stabilized on treatment for at least 8 weeks++Sustained elevated supine blood pressure exceeding 140/90 mmHg or notable resting tachycardia or blood pressure below 90/40 mmHg++Have taken any other investigational medications within past 3 months++Body mass index (BMI) of more than 40 kg/m2

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 

Who Is the General Study Contact?

For more information about this trial and its study sites, please call 1-888-662-6728 (U.S. only) or email genentechclinicaltrials@druginfo.com. Reference study ID number BP25543.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Hoffmann-La Roche

Source: ClinicalTrials.gov ID: NCT01436955